Uterine bleeding in breast cancer patients: Insights from a 5-year institutional review

Le résumé fourni par la source

Objectives: Uterine bleeding is an infrequent symptom in breast carcinoma patients, primarily linked to Tamoxifen therapy and less commonly to secondary malignancies or metastatic spread. The objective of this study was to ascertain the aetiology of uterine bleeding within a 5-year cohort of breast carcinoma patients. Material and Methods: A retrospective analysis included breast carcinoma patients who underwent endometrial or cervical biopsy for the evaluation of uterine bleeding were included in the review. All histology slides and radiology scans were meticulously reviewed. Patient clinical details were documented through the electronic medical records. Categorical variables were presented as frequencies and percentages. All statistical analyses were performed on SPSS. Results: Among the 4,543 breast carcinoma patients registered at our tertiary care oncology centre, only 45 patients (0.9%) underwent endometrial/cervix biopsy for pathologies in the gynaecological tract. Uterine bleeding was the most common indication, accounting for 29/45 (64.4%) cases, predominance attributed to structural causes according to the PALM-COEIN classification. Malignancies and premalignant lesions were detected in the majority of cases, comprising 37.7% of the cohort, while benign endometrial polyps represented the second most at 31%. Conclusion: These results highlight the critical necessity for comprehensive patient education and implementation of rigorous surveillance protocols to monitor uterine pathologies within this patient population.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.